STOCK TITAN
  1. Home
  2. News
  3. CPIX

Cumberland Pharmaceuticals Inc. - CPIX STOCK NEWS

Welcome to our dedicated news page for Cumberland Pharmaceuticals (Ticker: CPIX), a resource for investors and traders seeking the latest updates and insights on Cumberland Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cumberland Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cumberland Pharmaceuticals's position in the market.

News
NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS
Rhea-AI Summary
Cumberland Pharmaceuticals Inc. releases a Special Report showcasing the safety and efficacy of intravenous ibuprofen (IVIB) for pain and fever treatment in adults, children, and infants. The report emphasizes the need for non-opioid options in pain management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
News
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
Rhea-AI Summary
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) had a successful year in 2023 with $40 million in net revenues and $6 million in cash generated from operations. The company ended the year with $82 million in total assets, including $18 million in cash, $53 million in liabilities, and $30 million in shareholders' equity. Key highlights include expanded FDA approval for Caldolor to treat infants, positive clinical study results for Caldolor in newborns, and the passage of the federal NOPAIN Act. Cumberland also expanded its oncology sales division, published pediatric study results for Vibativ, and updated its sustainability metrics. The company is advancing its ifetroban product candidate in Phase II clinical trials and developing a treatment for Idiopathic Pulmonary Fibrosis. Financially, Cumberland reported a net loss of $6.3 million for 2023, with adjusted earnings of $2.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
earnings
-
News
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS
Rhea-AI Summary
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) will release its annual 2023 financial results and provide a company update on March 5, 2024. The company focuses on unique products for hospital acute care, gastroenterology, and oncology. FDA-approved brands include Acetadote, Caldolor, Kristalose, Omeclamox-Pak, Sancuso, Vaprisol, and Vibativ. Phase II clinical programs are ongoing for ifetroban in cardiomyopathy and Idiopathic Pulmonary Fibrosis. Cumberland Pharmaceuticals is committed to improving patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.29%
Tags
earnings
News
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reports combined revenues of $10.1 million in Q3 2023, net loss of $1.0 million, and $30.2 million year to date. Recent developments include a new bank credit facility, a new Vibativ pediatric study publication, expectations for special Medicare reimbursement for Caldolor, Sancuso acquisition, Vaprisol supply update, and progress in clinical development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.71%
Tags
earnings
-
News
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS
Rhea-AI Summary
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) will release its Q3 2023 financial results and provide a company update on November 7, 2023. The company specializes in high-quality prescription brands for hospital acute care, gastroenterology, and oncology. Their FDA-approved portfolio includes Acetadote, Caldolor, Kristalose, Omeclamox-Pak, Sancuso, Vaprisol, and Vibativ. Cumberland also has Phase II clinical programs for ifetroban and received FDA clearance for a Phase II study on Idiopathic Pulmonary Fibrosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.1%
Tags
earnings
-
News
NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE
Rhea-AI Summary
Cumberland Pharmaceuticals announces results of clinical study on Vibativ in pediatric patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
none
News
Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023
Rhea-AI Summary
Cumberland Pharmaceuticals Inc. announces improved financial results and positive earnings for Q2 2023. Revenue increased by 6% YoY and 18% sequentially. Net income for H1 2023 was $1.1 million. Adjusted earnings for H1 2023 were $4.0 million. Total assets at the end of June 2023 were $89.4 million. FDA granted fee waivers totaling $2.8 million. Cumberland acquired U.S. rights to Sancuso, an FDA-approved prescription patch for preventing nausea and vomiting in chemotherapy patients. Nordic Pharma assumed responsibility for RediTrex product line in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.38%
Tags
earnings
-
News
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
earnings
-
News
NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
none
News
CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Stock CPIX logo
Cumberland Pharmaceuticals Inc.

Nasdaq:CPIX

CPIX Rankings

#5060 Ranked by Market Cap
#3153 Ranked by Stock Gains
N/A Ranked by Dividends

CPIX Stock Data

23.11M
8.02M
44.06%
15.57%
0.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Nashville

About CPIX

cumberland pharmaceuticals is a specialty pharmaceutical company whose mission is to acquire currently marketed and late-stage development pharmaceutical products and grow them through marketing to targeted, underserved physician segments. cumberland is dedicated to providing high quality products which address unmet medical needs.